<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04685421</url>
  </required_header>
  <id_info>
    <org_study_id>2020005RI</org_study_id>
    <nct_id>NCT04685421</nct_id>
  </id_info>
  <brief_title>Liposomal Bupivacaine Pharmacokinetic Study After Median Sternotomy Incision Infiltration in a Pediatric Cardiac Surgery</brief_title>
  <official_title>Liposomal Bupivacaine Pharmacokinetic Study After Median Sternotomy Incision Infiltration in a Pediatric Cardiac Surgery</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Nicklaus Children's Hospital f/k/a Miami Children's Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Nicklaus Children's Hospital f/k/a Miami Children's Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to determine the plasma concentration of bupivacaine at various&#xD;
      time points after Exparel (bupivacaine liposome injectable suspension, Pacira&#xD;
      Pharmaceuticals, Inc., Parsippany, NJ) is injected subcutaneously for median sternotomy&#xD;
      incisions in pediatric cardiac surgery patients.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      To determine the pharmacokinetic profile and peak bupivacaine plasma concentration with the&#xD;
      use of an Exparel/bupivacaine mixture in children ages two through seventeen. We will be&#xD;
      collecting blood samples at different times during 96 hours or until the patient is&#xD;
      discharged from the hospital. There will be two different groups participating in the study&#xD;
      alternating the times in which the blood samples will be collected. We hypothesize that peak&#xD;
      plasma concentration will be significantly less than the toxic plasma concentration.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 15, 2021</start_date>
  <completion_date type="Anticipated">January 6, 2023</completion_date>
  <primary_completion_date type="Anticipated">January 6, 2022</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>Study population of 30 pediatric cardiac surgery patients undergoing elective operations between the ages of two through seventeen years.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Bupivacaine-Exparel levels</measure>
    <time_frame>96 hours</time_frame>
    <description>To determine plasma bupivacaine levels after the use of Exparel 1.3% admixed with 0.25% bupivacaine and 0.9% Normal Saline in pediatric cardiac surgery patients ages two through seventeen years of age.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Cardiac Conditions</condition>
  <arm_group>
    <arm_group_label>Liposomal Bupivacaine PK</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Liposomal Bupivacaine PKs collections up to 96 hours on children from 2 to 17 years in pediatric cardiac surgeries.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bupivacaine liposome</intervention_name>
    <description>Liposomal Bupivacaine PKs collections up to 96 hours on children from 2 to 17 years in pediatric cardiac surgeries.</description>
    <arm_group_label>Liposomal Bupivacaine PK</arm_group_label>
    <other_name>Bupivacaine liposome PKs</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Every elective pediatric surgery patient ages two through seventeen years old,&#xD;
             inclusive.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients who fall outside of the age range for the study will be excluded. -Patients&#xD;
             known to have had an anaphylactic or severe reaction to the drug or its components&#xD;
             will not be enrolled. Any with Significant Liver Disease will also be excluded.&#xD;
             Emergency patients will be excluded. Pregnant patients will be excluded.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>2 Years</minimum_age>
    <maximum_age>17 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Christopher F Tirotta, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Nicklaus Children's Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jenny F Esteves, MBA/MHSA</last_name>
    <phone>786-624-2854</phone>
    <email>jenny.esteves@nicklaushealth.org</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Moya Chang</last_name>
    <phone>786-624-3529</phone>
    <email>moya.chang@nicklaushealth.org</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Nickalus Children's Hospital f/k/a Miami Children's Hospital</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33155</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jenny Esteves, RRC</last_name>
      <phone>786-624-2854</phone>
      <email>jenny.esteves@nicklaushealth.org</email>
    </contact>
    <contact_backup>
      <last_name>Apeksha Gupta, Statistician</last_name>
      <phone>305-663-8593</phone>
      <email>apeksha.gupta@nicklaushealth.org</email>
    </contact_backup>
    <investigator>
      <last_name>Christopher Tirotta, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.nicklauschildrens.org</url>
    <description>Nicklaus Children's Hospital</description>
  </link>
  <reference>
    <citation>Chughtai M, Sultan AA, Hudson B, Goodwin RC, Seif J, Khlopas A, Bena J, Jin Y, Gurd DP, Kuivila TE, Ballock RT. Liposomal Bupivacaine Is Both Safe and Effective in Controlling Postoperative Pain After Spinal Surgery in Children: A Controlled Cohort Study. Clin Spine Surg. 2020 Dec;33(10):E533-E538. doi: 10.1097/BSD.0000000000000996.</citation>
    <PMID>32324672</PMID>
  </reference>
  <reference>
    <citation>Crowley JS, McLean P, Gabriel RA, Cronin B, Hsieh S, Englar K, Said E, Lance S, Gosman A. The Association of Liposomal Bupivacaine on Opioid Consumption in the Pediatric Alveolar Cleft Population. J Craniofac Surg. 2020 Jun;31(4):1078-1081. doi: 10.1097/SCS.0000000000006310.</citation>
    <PMID>32195834</PMID>
  </reference>
  <reference>
    <citation>Cohen B, Glosser L, Saab R, Walters M, Salih A, Zafeer-Khan M, Rivas E, Zhang K, Schacham NY, Chodavarapu P, Essber H, Chelnick D, Raza S, Hanline C, Khoshknabi D, Yang D, Seif J, Chhabada S, Turan A. Incidence of adverse events attributable to bupivacaine liposome injectable suspension or plain bupivacaine for postoperative pain in pediatric surgical patients: A retrospective matched cohort analysis. Paediatr Anaesth. 2019 Feb;29(2):169-174. doi: 10.1111/pan.13561. Epub 2018 Dec 31.</citation>
    <PMID>30521078</PMID>
  </reference>
  <reference>
    <citation>Cloyd C, Moffett BS, Bernhardt MB, Monico EM, Patel N, Hanson D. Efficacy of liposomal bupivacaine in pediatric patients undergoing spine surgery. Paediatr Anaesth. 2018 Nov;28(11):982-986. doi: 10.1111/pan.13482. Epub 2018 Sep 11.</citation>
    <PMID>30207019</PMID>
  </reference>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>December 22, 2020</study_first_submitted>
  <study_first_submitted_qc>December 22, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">December 28, 2020</study_first_posted>
  <last_update_submitted>September 15, 2021</last_update_submitted>
  <last_update_submitted_qc>September 15, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 16, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Nicklaus Children's Hospital f/k/a Miami Children's Hospital</investigator_affiliation>
    <investigator_full_name>Christopher Tirotta, MD, MBA</investigator_full_name>
    <investigator_title>Chief of Anesthesiology Department</investigator_title>
  </responsible_party>
  <keyword>pediatric cardiac surgery</keyword>
  <keyword>median sternotomy incision</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Surgical Wound</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bupivacaine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>De-identified will be posted in website.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Informed Consent Form (ICF)</ipd_info_type>
    <ipd_time_frame>one year after study closure</ipd_time_frame>
    <ipd_access_criteria>Information will be provided by request to the PI</ipd_access_criteria>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

